World Vaccines Market: Vaccine Segments Analysis, Vaccine Cases and Future Forecast

27 Jan 2011 • by Natalie Aster

“For decades vaccines were a neglected corner of the drugs business, with old technology, little investment and abysmal profit margins. Many firms sold their vaccine divisions to concentrate on more profitable drugs. This troubled public-health experts because vaccines are a highly effective way of dealing with diseases.”

Happily, a renaissance is under way. World vaccine sales vaulted from US$ 10.1 Billion in 2005 to US$ 23 Billion in 2009. Insurers and governments in the rich world have started to pay higher prices: firms making new vaccines against pneumococcal disease or the human papilloma virus earning rich dividends.

The report “World Vaccines Market: Vaccine Segments Analysis, Vaccine Cases and Future Forecast” by Renub Research talks about the vaccines market worldwide. The report gives the past, present scenario on the vaccines market and also forecast on future of vaccines market. Such as market size of Pediatric Combinations & Booster, Pediatric Enhanced Combination, Pediatric Proprietary, Travel & Endemic Vaccines, Other Adults (HPV, Zoster etc), Bio-Protection. The report covered different companies market share in vaccines segment. It also forecasts the sales of the key vaccines brands like Gardasil, Fluzone, Prevnar, Cervarix, Infanrix/Pediarix, Hepatitis (Engerix/Fendrix, Havrix, Twinrix).

Report Details:

World Vaccines Market: Vaccine Segments Analysis, Vaccine Cases and Future Forecast

Published: January 2011
Pages: 117
Price: US$ 1,100.00

Report Sample Abstract:

As growth in sales of vaccines has became higher than the traditional business all major pharmaceutical companies are eyeing the vaccine market as driver for their growth. Many mergers and acquisition have taken place in this space as consolidation has become the keyword for future growth. With companies consolidating they can focus better in the market and keep their profit margins high. Recently, pharmaceutical company Pfizer acquired Wyeth, Merck acquired Schering Plough and Sanofi acquired Shantha Biotechnics.

Earlier biggest market of vaccines used to be basic pediatrics. But now more or less it’s losing its pre eminence due to expiry of patents on drugs and inclusion of basic pediatrics in basic healthcare provided by government at grass roots level. The growth in the vaccine industry is coming from the sectors like Pediatric Proprietary vaccine and Pediatric Enhanced Combination. According to our research findings Pediatric Proprietary vaccine was having 27% market in 2009 and it is expected to increase to 32% by 2015. Due to rising fear of terrorism Bio- Bio-protection vaccine future is also shinning. The Bio-protection vaccines market is expected to grow with a CAGR of 12.08% percent from 2009 to 2015.

Market for Meningitis vaccine and Rotavirus vaccine has crossed US$ 1 Billion by 2009. Seasonal flu vaccine market is forecasted to be more than US$ 7 Billion by 2016. Vaccines like Prevnar (Pneumococcal vaccines), Gardasil (Cervical cancer vaccines) have crossed the sales of US$ 1 Billion by 2007. In fact Prevnar became the first vaccine to reach nearly US$ 3 Billion annual sales by 2009

In terms of number of cases Measles, Mums, Rubella, Diphtheria, Pertussis and Tetanus cases have shown a decline continuously from 2001 till 2009. However, Yellow Fever is an exception to this whose number of cases has increased. Geographically US will continue to lead the vaccines market followed by Europe. Japanese vaccine market has also started to open up further from regulatory and political barriers.

More information can be found in the report “World Vaccines Market: Vaccine Segments Analysis, Vaccine Cases and Future Forecast” by Renub Research.

To order the report or ask for sample pages contact


MarketPublishers, Ltd.
Mrs. Alla Martin
Tel: +44 208 144 6009
Fax: +44 207 900 3970